Cellular senescence changes and their association with brain structure in schizophrenia and major depressive disorder
This study reveals that while both schizophrenia and major depressive disorder are associated with elevated cellular senescence markers (SASP indices), these markers correlate with localized reductions in specific cortical surface areas related to auditory and language processing in schizophrenia rather than with global brain aging.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
People with schizophrenia and major depressive disorder often face a shorter lifespan than the general population, a reality driven not just by lifestyle factors but by a deeper, biological acceleration of aging. Inside our bodies, cells have a natural limit to how many times they can divide; once they reach this limit, they stop growing but do not die. Instead, they enter a state called cellular senescence. Think of these cells as retired workers who, instead of leaving the building, stay on and constantly complain, releasing a cloud of inflammatory chemicals that irritate their neighbors and damage the surrounding tissue. This cloud of chemicals is known as the senescence-associated secretory phenotype, or SASP. While scientists have long suspected that this process might be happening too early or too intensely in people with severe mental illness, the exact link between these aging cells and the physical structure of the brain has remained a mystery.
A team of researchers at the University of Tokyo and Harvard Medical School set out to solve this puzzle by looking at the blood and brains of 119 people. The group included individuals diagnosed with schizophrenia, individuals with major depressive disorder, and healthy volunteers. The scientists collected blood samples to measure a specific set of proteins associated with that inflammatory "cloud" of aging cells. They combined these measurements into a single score, a composite index that acts like a report card for how much cellular aging is happening in the body. At the same time, the participants underwent detailed MRI scans of their brains. The researchers used these scans to calculate a "brain-predicted age," a number that estimates how old a brain looks based on its structure, and compared it to the person's actual age to see if the brain appeared older than it should be. They also measured the size and thickness of specific brain regions to see if the aging cells were shrinking or thinning specific parts of the brain.
The study confirmed what many had suspected: the blood of people with both schizophrenia and major depressive disorder showed significantly higher levels of these aging-related proteins compared to the healthy volunteers. In other words, the cellular "cloud" of inflammation was thicker in both groups of patients. This finding suggests that accelerated biological aging is a shared feature of these two distinct disorders. However, when the researchers looked at the brain scans, the story became more complex. They found that while people with schizophrenia did have brains that looked older than their years, this "brain age" gap did not correlate with the level of aging proteins in their blood. The same was true for the group with depression. This lack of a direct link between the blood markers and the overall age of the brain suggests that the aging process in the body and the aging process in the brain might be happening independently of one another in these patients.
The most revealing discovery came when the scientists stopped looking at the brain as a whole and started examining specific neighborhoods within it. They found a clear, negative connection between the aging proteins and the surface area of two very specific regions in the brains of people with schizophrenia: the left transverse temporal gyrus and the right inferior frontal gyrus. These areas are critical for hearing, language, and processing complex thoughts. The higher the level of aging proteins in a patient's blood, the smaller the surface area of these specific brain regions tended to be. This relationship was not seen in the healthy volunteers or in the patients with depression, nor was it found in other parts of the brain. It appears that the cellular aging process is not uniformly shrinking the entire brain, but rather targeting these specific zones that are already known to be vulnerable in schizophrenia.
These findings offer a new perspective on how mental illness might interact with the body's aging mechanisms. The data suggests that while the body's cellular aging is elevated across both schizophrenia and depression, its physical impact on the brain is highly localized. In schizophrenia, the inflammatory signals from aging cells may be contributing to the shrinkage of specific brain regions responsible for language and auditory processing, which are often the sites of symptoms like hallucinations or disorganized thinking. The study does not prove that these aging cells cause the disease, nor does it suggest that treating them will cure the condition, but it provides a concrete biological map of where the damage is occurring. By identifying that the aging process targets specific brain structures rather than the whole organ, the research points toward a more precise understanding of the neural underpinnings of schizophrenia, distinguishing it from the broader aging patterns seen in depression.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.